Dacai Xu

Dacai Xu

Auto-generated profile, based on publicly available information

Dacai Xu

Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, China; Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Experimental Cell Research
Verified
Journal Article
Open access
DXDacai Xu
Dacai Xu
DZDonghui Zhang
Donghui Zhang
WWWenlu Wei
Wenlu Wei
CZChong Zhang
Chong Zhang
UBA5, a ubiquitin-like activated enzyme involved in ufmylation and sumoylation, presents a viable target for pancreatic and breast cancer treatments, yet its role in lung adenocarcinoma (LUAD) remains underexplored. This study reveals UBA5's tumor-promoting effect in LUAD, as evidenced by its upregulation in patients and positive correlation with TNM stages. Elevated UBA5 levels predict poor outcomes for these patients. Pharmacological inhibition of UBA5 using DKM 2-93 significantly curtails the growth of A549, H1299, and cisplatin-resistant A549 (A549/DDP) LUAD cells in vitro. Additionally, UBA5 knockdown via shRNA lentivirus suppresses tumor growth both in vitro and in vivo. High UBA5 expression adversely alters the tumor immune microenvironment, affecting immunostimulators, MHC molecules, chemokines, receptors, and immune cell infiltration. Notably, UBA5 expression correlates positively with M2 macrophage infiltration, the predominant immune cells in LUAD. Co-culture experiments further demonstrate that UBA5 knockdown directly inhibits M2 macrophage polarization and lactate production in LUAD. Moreover, in vivo studies show reduced M2 macrophage infiltration following UBA5 knockdown. UBA5 expression is also associated with increased tumor heterogeneity, including tumor mutational burden, microsatellite instability, neoantigen presence, and homologous recombination deficiency. Experiments indicate that UBA5 overexpression promotes cisplatin resistance in vitro, whereas UBA5 inhibition enhances cisplatin sensitivity in both in vitro and in vivo settings. Overall, these findings suggest that targeting UBA5 inhibits LUAD by impeding cancer cell proliferation, M2 macrophage polarization, and cisplatin resistance.

30 May 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
LYLeyi Yao
Leyi Yao
SYShuhui Ye
Shuhui Ye
DXDacai Xu
Dacai Xu
Cuproptosis, a recently identified form of regulated cell death, is triggered by intracellular copper accumulation, leading to subsequent protein lipoylation or pyruvate uptake. The ubiquitin-proteasome system plays a key role in copper-induced cell death. This study aims to identify the deubiquitinase-mediated regulation of cuproptosis in hepatocellular carcinoma. UCHL3 was identified as a key regulator of cuproptosis via the deubiquitinase siRNA library screening. UCHL3 knockdown inhibited elesclomol-CuCl2-induced cuproptosis, whereas its overexpression enhanced cuproptosis. Correspondingly, UCHL3 inhibition suppressed cuproptosis, while activation of UCHL3 promoted it. Ubiquitinome profiling revealed that UCHL3 modulates the pyruvate biosynthetic process, cellular response to metal ions, and hypoxia. Its downstream effects were enriched in glycolysis and the HIF-1 signaling pathway. PKM2 emerged as a key node within the UCHL3 substrate network. Wild-type UCHL3, instead of its active site mutant (C95A), deubiquitinated and stabilized PKM2. The PKM2 K206R mutation prevented PKM2 ubiquitination. UCHL3 directly interacted with PKM2. Pharmacological or genetic inhibition of PKM2 impaired cuproptosis in hepatocellular carcinoma. Conversely, overexpression of wild-type PKM2 or activation of PKM2 promoted cuproptosis. Both UCHL3 and PKM2 promoted pyruvate biosynthesis. Moreover, pyruvate directly enhanced cuproptosis induced by elesclomol-CuCl2 in HCC. In vivo, UCHL3 facilitated cuproptosis induced by elesclomol-CuCl2. In conclusion, UCHL3 enhances cuproptosis by deubiquitinating and stabilizing PKM2 at the K206 site in hepatocellular carcinoma, presenting a novel therapeutic avenue for treatment.

3 November 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
HHHongbiao Huang
Hongbiao Huang
YXYujie Xiang
Yujie Xiang
YDYuanfei Deng
Yuanfei Deng
QLQing Liu
Qing Liu
GCGengxi Cai
Gengxi Cai
YLYuning Liao
Yuning Liao